Novo Nordisk’s weight problems drug Wegovy was cleared by U.S. regulators on Friday to deal with an more and more widespread liver illness, including to the listing of circumstances for which the blockbuster remedy is now permitted.
The Meals and Drug Administration granted accelerated approval to Wegovy for sufferers with metabolic dysfunction-associated steatohepatitis, or MASH, with reasonable to superior liver scarring. The choice was primarily based on Section 3 outcomes displaying that the drug helped enhance liver scarring, or fibrosis, and resolve signs.
Many individuals with weight problems develop fatty liver illness, which might then progress to a extreme kind that’s MASH. MASH causes fibrosis, which might then advance to much more severe scarring referred to as cirrhosis, which then results in liver most cancers or the necessity for a liver transplant.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.